Skip to content ↓

Topic

Broad Institute

Download RSS feed: News Articles / In the Media / Audio

Displaying 1 - 15 of 143 news clips related to this topic.
Show:

San Francisco Chronicle

Prof. James Collins and his colleagues are using AI to develop new compounds to combat the growing problem of antibiotic resistant bacteria, reports Lisa M. Krieger for the San Francisco Chronicle. Thus far, “Collins and his colleagues have synthesized several compounds that combat hard-to-treat infections of gonorrhea and MRSA,” writes Krieger. “These techniques are also being harnessed to fight diseases, like cancer, lupus and arthritis.” 

Financial Times

Prof. James Collins speaks with Financial Times reporter Patrick Temple-West about his work using AI to design new antibiotic compounds to combat drug-resistant bacteria. “At present, the [AI] models are doing quite well at designing compounds that can attack in a Petri dish,” says Collins. 

Fast Company

Researchers at MIT are using AI systems to design new molecules for potential antibiotics, research that is “aimed at the growing challenge of antibiotic-resistant infections,” reports Adele Peters for Fast Company. “The number of resistant bacterial pathogens has been growing, decade upon decade,” says Prof. James Collins. “And the number of new antibiotics being developed has been dropping, decade upon decade.” 

Forbes

Jon Arizti Sanz PhD '24 and postdoctoral associate Ren Hao Soon have been named to the 2025 cohort of Schmidt Science Fellows, reports Michael T. Nietzel for Forbes. “This year’s class of 32 fellows are all recent PhDs who’ve been identified as some of the most outstanding early-career scientists in the world,” explains Nietzel.

STAT

MIT has multiple projects represented in this year’s STAT Madness, a bracket-style competition “highlighting important scientific advances emerging from labs at the nation’s universities, medical schools, and other U.S. research institutions and companies,” reports STAT staff.

The Boston Globe

Researchers at MIT and elsewhere have found that the long-term consumption of “processed red meat, such as hot dogs, sausage, and bacon, is linked to an elevated risk of dementia,” reports Kay Lazar for The Boston Globe. The researchers “found that eating about two servings per week of processed red meat, which includes some cold cuts, correlated with a 13 percent higher risk of dementia compared to those who ate less than roughly three servings a month,” reports Lazar. 

Forbes

MIT Profs. Angela Belcher, Emery Brown, Paula Hammond and Feng Zhang have been honored with National Medals of Science and Technology, reports Michael T. Neitzel for Forbes. Additionally, R. Lawrence Edwards '76 received a National Medal of Science and Noubar Afeyan PhD '87, a member of the MIT Corporation, accepted a National Medal on behalf of Moderna. The recipients have been awarded “the nation’s highest honors for exemplary achievements and leadership in science and technology,” explains Neitzel. 

The New Yorker

New Yorker reporter Dhruv Khullar spotlights how researchers from across MIT are using AI to advance drug development. Khullar highlights the MIT Jameel Clinic, the Broad Institute and various faculty members for their efforts in bridging the gap between AI and drug research. “With AI, we’re getting that much more efficient at finding molecules—and in some cases creating them,” says Prof. James Collins. “The cost of the search is going down. Now we really don’t have an excuse.”

USA Today

Sonia Vallabh and Eric Minikel, senior group leaders from the Broad Institute have created a gene-editing tool to combat prion diseases, reports Karen Weintraub for USA Today. The approach “should also work against diseases such as Huntington's, Parkinson's, ALS and even Alzheimer's, which result from the accumulation of toxic proteins,” Weintraub writes.

HealthDay News

MIT scientists have shown a simple paper-strip test can detect the flu and identify the specific strain, which could prove useful in improving outbreak response and infection care, writes Dennis Thompson for HealthDay. Jon Arizti-Sanz PhD ’24 says “being able to tease apart what strain or subtype of influenza is infecting a patient has repercussions both for treating them and public health interventions.” 

Boston Herald

Researchers from MIT and elsewhere are investigating the “pathways, risk factors, and molecules” involved in the development of colorectal cancer, reports Rick Sobey for The Boston Herald. “The research team has uncovered contributing causes to this rise in early-onset cases, including: overweight/obesity, physical inactivity, poor diet, and alterations in the gut microbiome,” writes Sobey.

Boston.com

Prof. Feng Zhang has been named to STAT’s 2024 STATUS List, which highlights the leaders shaping the future of health and life sciences, reports Dialynn Dwyer for Boston.com. “Among the companies he’s co-founded is Editas Medicine, which as of late 2023 was now the official holder of patent rights to the CRISPR-Cas9 gene editing tool used in the sickle cell therapy Casgevy, and Aera Therapeutics, which in February 2023 raised $193 million in venture funding to develop protein nanoparticles as a way of delivering gene editing,” Dwyer writes.

The Boston Globe

Omar Abudayyeh '12, PhD '18 and Jonathan Gootenberg '13 speak with Robert Weisman at The Boston Globe about their deep-rooted working relationship, which began as undergraduates at MIT and has gone on to include joint appointments at the McGovern and Broad Institutes and multiple startups. “Science is difficult, and it’s great to have someone to do it with,” said Gootenberg. “You got to work with people you enjoy hanging out with.”
 

STAT

Prof. Jonathan Weissman and his colleagues have developed a new tool for monitoring changes in human blood cells, which could one day help researchers predict disease risk, reports Megan Molteni for STAT. “The technology paves the way for a day in the not too distant future where it is conceivable that from a simple blood draw, a doctor could get a sense of what’s going on in that patient’s bone marrow,” writes Molteni, “picking up perturbations there that could help predict a diverse range of diseases.”

Fierce Biotech

In a new paper, MIT researchers detail how they have used AI techniques to discover a class of “of antibiotics capable of killing methicillin-resistant Staphylococcus aureus (MRSA),” reports Helen Floresh for Fierce Biotech. “This paper announces the first AI-driven discovery of a new class of small molecule antibiotics capable of addressing antibiotic resistance, and one of the few to have been discovered overall in the past 60 years,” says postdoctoral fellow Felix Wong.